UNSPSC 51334410: Lusaperidone

This classification denotes an antipsychotic agent with the molecular formula C22H21N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5KTD2O86CB, chemically known as 3-(2-(3,4-dihydrobenzofuro(3,2-c)pyridin-2(1h)-yl)ethyl)-2-methyl-4h-pyrido(1,2-a)pyrimidin-4-one. but generally known as lusaperidone, which bears US NIH Compound Identifier 3045401. The term LUSAPERIDONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 3, 2000, List 44).

Most nations schedule lusaperidone under HS 29349990 and SITC 51579. As of Q4 2014, LUSAPERIDONE remains the US FDA Preferred Term for this commodity. Lusaperidone bears US NLM identifiers UMLS ID C2983866 and NCI Concept Code C90760. SMILES: CC1=C(C(=O)N2C=CC=CC2=N1)CCN3CCC4=C(C3)C5=CC=CC=C5O4.

UNSPSC 51334410 Lusaperidone is a Commodity code, but the recent state and local opportunities tagged under it involve the procurement of pharmaceutical products—specifically naloxone, generic multi-source pharmaceuticals, and over-the-counter products—rather than lusaperidone in isolation. State and local buyers are sourcing these medications and drug-management systems to support community health, pharmacy benefit programs, and emergency response initiatives. The solicitations reflect a mix of direct-purchase procurements by individual jurisdictions and cooperative purchasing arrangements spanning multiple states. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, administered by the Minnesota Department of Administration). The work involves establishing supply contracts with manufacturers, negotiating pricing through wholesaler networks, and ensuring compliance with FDA regulations, cGMP certification, and Drug Supply Chain Security Act requirements.

Recent activity spans Florida, Texas, and Minnesota-led multistate participation. Seminole County issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its community health building, with bids due July 26, 2023 (note: the source dates appear inconsistent; the posting is recent but the deadline is historical). The Texas HHS Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, reflecting early-stage market research before formal competitive solicitation. MMCAP posted RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, requiring manufacturers to supply through three authorized wholesalers with pricing weighted 75 percent in evaluation and contract effectiveness July 1, 2026. These opportunities signal demand for pharmaceutical supply contracts combining fixed-price and net-price models, wholesaler-network integration, and compliance-heavy procurement frameworks serving state and local health systems.